How I treat anticoagulated patients undergoing an elective procedure or surgery

Blood

Volumn 120, Issue 15, 2012, Pages 2954-2962

  Spyropoulos, Alex C ^a   Douketis, James D ^b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; DABIGATRAN; HEPARIN; RIVAROXABAN; WARFARIN;

ABDOMINAL HYSTERECTOMY; ADULT; AGED; ANGIOGRAPHY; ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; AORTA VALVE PROSTHESIS; ARTHROSCOPY; BRONCHOSCOPY; CANCER SURGERY; CARPAL TUNNEL SYNDROME; CATARACT EXTRACTION; CATHETER REMOVAL; CENTRAL VENOUS CATHETER; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; COLON RESECTION; COLONOSCOPY; CORONARY ARTERY BYPASS SURGERY; CREATININE CLEARANCE; CURETTAGE; DIABETES MELLITUS; DRUG HALF LIFE; DRUG WITHDRAWAL; ELECTIVE SURGERY; ENDOVASCULAR ANEURYSM REPAIR; EYE SURGERY; FEMALE; GASTROINTESTINAL ENDOSCOPY; HEART ATRIUM FIBRILLATION; HEART VALVE REPLACEMENT; HERNIOPLASTY; HIP ARTHROPLASTY; HUMAN; HYDROCELE; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; KIDNEY BIOPSY; KIDNEY FAILURE; KNEE ARTHROPLASTY; LABORATORY TEST; LAMINECTOMY; LAPAROSCOPIC SURGERY; LOCAL ANESTHESIA; LUNG EMBOLISM; LYMPH NODE BIOPSY; LYMPH NODE DISSECTION; MALE; MITRAL VALVE PROSTHESIS; MONITORING; NEEDLE BIOPSY; OBESITY; PERIOPERATIVE PERIOD; POLYPECTOMY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RECTUM HEMORRHAGE; REVIEW; SPINAL ANESTHESIA; THROMBIN TIME; TOOTH EXTRACTION; TRANSURETHRAL RESECTION; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

EID: 84867881603     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-06-415943     Document Type: Review

References (65)

1. Douketis JD, Berger PB, Dunn AS, et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Ed). Chest 2008;133(6 Suppl):299S-339S. (Pubitemid 351894915)
2. Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med. 1997;336(21):1506-1511.
3. Caliendo FJ, Halpern VJ, Marini CP, et al. Warfarin anticoagulation in the perioperative period: is it safe? Ann Vasc Surg. 1999;13(1):11-16. (Pubitemid 29048453)
4. Dunn AS, Turpie AG. Perioperative management of patients receiving oral anticoagulants: a systematic review. Arch Intern Med. 2003;163(8):901-908. (Pubitemid 36522737)
5. Dentali F, Pignatelli P, Malato A, et al. Incidence of thromboembolic complications in patients with atrial fibrillation or mechanical heart valves with a subtherapeutic international normalized ratio: a prospective multicenter cohort study. Am J Hematol. 2012;87(4):384-387.
6. Spyropoulos AC, Douketis JD. Guidelines for antithrombotic therapy: periprocedural management of antithrombotic therapy and use of bridging anticoagulation. Int Angiol. 2008;27(4):333-343.
7. Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed.: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e326S-e350S.
8. Spyropoulos AC. Bridging of oral anticoagulation therapy for invasive procedures. Curr Hematol Rep. 2005;4(5):405-413.
9. Spyropoulos AC. Bridging therapy and oral anticoagulation: current and future prospects. Curr Opin Hematol. 2010;17(5):444-449.
10. Douketis JD. Pharmacologic properties of the new oral anticoagulants: a clinician-oriented review with a focus on perioperative management. Curr Pharm Des. 2010;16(31):3436-3441.
11. Kaatz S, Kouides PA, Garcia DA, et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol. 2012;87(Suppl 1):S141-S145.
12. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103(6):1116-1127.
13. Schulman S, Crowther MA. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood. 2012;119(13):3016-3023.
14. Healey JS, Eikelboom J, Douketis J, et al. Periprocedural bleeding and thromboembolic events with dabigatran compared to warfarin: results from the RE-LY randomized trial. Circulation. 2012;126(3):343-348.
15. Lindmarker P, Schulman S, Sten-Linder M, Wiman B, Egberg N, Johnsson H. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691Aallele in the coagulation factor V gene and the G20210Aallele in the prothrombin gene. DURAC Trial Study Group: Duration of anticoagulation. Thromb Haemost. 1999;81(5):684-689. (Pubitemid 29216550)
16. Schulman S, Majeed A. A benefit-risk assessment of dabigatran in the prevention of venous thromboembolism in orthopaedic surgery. Drug Safety. 2011;34(6):449-463.
17. Singer DE, AlbersGW, Dalen JE, GoAS, Halperin JL, Manning WJ. Antithrombotic therapy in atrial fibrillation: the SeventhACCP Conference on Antithrombotic and Thrombolytic Therapy [see comment]. Chest 2004;126(3 suppl):429S-456S. (Pubitemid 39302603)
18. Gage BF,Waterman AD, ShannonW, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285(22):2864-2870. (Pubitemid 32537350)
19. Kaatz S, Douketis JD, White RH, Zhou H. Can the CHADS2 score predict postoperative stroke risk in patients with chronic atrial fibrilation who are having elective non-cardiac surgery? J Thromb Haemost. 2011;9:P-WE-367.
20. Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation. 1994;89(2):635-641. (Pubitemid 24056190)
21. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 Suppl):204S-233S. (Pubitemid 39297955)
22. Tiede DJ, Nishimura RA, Gastineau DA, Mullany CJ, Orszulak TA, Schaff HV. Modern management of prosthetic valve anticoagulation. Mayo Clin Proc. 1998;73(7):665-680. (Pubitemid 28307726)
23. Lindberg F, Bergqvist D, Rasmussen I. Incidence of thromboembolic complications after laparoscopic cholecystectomy: review of the literature. Surg Laparosc Endosc. 1997;7(4):324-331.
24. Rowbotham BJ, Whitaker AN, Harrison J, Murtaugh P, Reasbeck P, Bowie EJ. Measurement of cross-linked fibrin derivatives in patients undergoing abdominal surgery: use in the diagnosis of postoperative venous thrombosis. Blood Coagul Fibrinolysis. 1992;3(1):25-31.
25. Wahl MJ. Drug interactions. J Am Dent Assoc. 1999;130:1270(9):1272.
26. Douketis JD, Johnson JA, Turpie AG. Low-molecular- weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Arch Intern Med. 2004;164(12):1319-1326. (Pubitemid 38828883)
27. Weibert RT. Oral anticoagulant therapy in patients undergoing dental surgery. Clin Pharm. 1992;11(10):857-864.
28. American Society for Gastrointestinal Endoscopy. Technology Assessment Status Evaluation-update: endoscopic band ligation. November, 1996. Gastrointest Endosc. 1998;47(6):573-575.
29. Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin: overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med. 1988;318(18):1162-1173.
30. Carrier M, Le Gal G, Wells PS, Rodger MA. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med. 2010;152(9):578-589.
31. Douketis JD, Gu CS, Schulman S, Ghirarduzzi A, Pengo V, Prandoni P. The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism. Ann Intern Med. 2007;147(11):766-774. (Pubitemid 351664441)
32. Martinelli J, Jiminez A, Rabago G, Artiz V, Fraile J, Farre J. Mechanical cardiac valve thrombosis: is thrombectomy justified? Circulation. 1991;84(5 Suppl):III70S-III75S.
33. Longstreth WT Jr, Bernick C, Fitzpatrick A, et al. Frequency and predictors of stroke death in 5888 participants in the Cardiovascular Health Study. Neurology. 2001;56(3):368-375. (Pubitemid 32144149)
34. Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med. 2003;139(11):893-900.
35. Morimoto Y, Niwa H, Minematsu K, Morimoto Y, Niwa H, Minematsu K. Hemostatic management of tooth extractions in patients on oral antithrombotic therapy. J Oral Maxillofac Surg. 2008;66(1):51-57. (Pubitemid 350236503)
36. Carter G, Goss A. Tranexamic acid mouthwash: a prospective randomized study of a 2-day regimen vs 5-day regimen to prevent postoperative bleeding in anticoagulated patients requiring dental extractions. Int J Oral Maxillofac Surg. 2003;32(5):504-507. (Pubitemid 38263350)
37. Kargi E, Babuccu O, Hosnuter M, Babuccu B, Altinyazar C. Complications of minor cutaneous surgery in patients under anticoagulant treatment. Aesthetic Plast Surg. 2002;26(6):483-485. (Pubitemid 36919367)
38. Jamula E, Schwalm JD, Douketis JD. Periprocedural anticoagulation practices in warfarin-treated patients who require elective angiography with or without percutaneous coronary intervention: a retrospective chart review. Thromb Res. 2010;125(4):351-352.
39. White RH, McKittrick T, Hutchinson R, Twitchell J. Temporary discontinuation of warfarin therapy: changes in the international normalized ratio. Ann Intern Med. 1995;122(1):40-42.
40. Hewitt RL, Chun KL, Flint LM. Current clinical concepts in perioperative anticoagulation. Am Surg. 1999;65(3):270-273. (Pubitemid 29114150)
41. Tinker JH, Tarhan S. Discontinuing anticoagulant therapy in surgical patients with cardiac valve prostheses. Observations in 180 operations. JAMA. 1978;239(8):738-739. (Pubitemid 8276469)
42. Woods K, Douketis JD, Kathirgamanathan K, Yi Q, Crowther MA. Low-dose oral vitamin K to normalize the international normalized ratio prior to surgery in patients who require temporary interruption of warfarin. J Thromb Thrombolysis. 2007;24(2):93-97.
43. Thachil J, Gatt A, Martlew V. Management of surgical patients receiving anticoagulation and antiplatelet agents. Br J Surg. 2008;95(12):1437-1448.
44. Dunn AS, Spyropoulos A, Turpie AG. Bridging therapy in patients on long-term oral anticoagulants who require surgery: the Prospective Perioperative Enoxaparin Cohort Trial (PROSPECT). J Thromb Haemost. 2007;5(11):2211-2218. (Pubitemid 47617873)
45. O'Donnell MJ, Kearon C, Johnson J, et al. Brief communication: preoperative anticoagulant activity after bridging low-molecular-weight heparin for temporary interruption of warfarin. Ann Intern Med. 2007;146(3):184-187. (Pubitemid 351650631)
46. Jaffer AK. Perioperative management of warfarin and antiplatelet therapy. Cleve Clin J Med. 2009;76(suppl 4):S37-S44.
47. Pengo V, Cucchini U, Denas G, et al. Standardized low-molecular-weight heparin bridging regimen in outpatients on oral anticoagulants undergoing invasive procedure or surgery: an inception cohort management study. Circulation. 2009;119(22):2920-2927.
48. Malato A, Saccullo G, Lo Coco L, et al. Patients requiring interruption of long-term oral anticoagulant therapy: the use of fixed sub-therapeutic doses of low-molecular-weight heparin. J Thromb Haemost. 2010;8(1):107-113.
49. Horlocker TT, Wedel DJ, Rowlingson JC, et al. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (3rd Ed). Reg Anesth Pain Med. 2010;35(1):64-101.
50. Siegal D, Yudin J, Kaatz S, Douketis JD, Lim W, Spyropoulos AC. Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates [published online head of print August 21, 2012]. Circulation. doi:10.1161/CIRCULATIONAHA.112.105221.
51. Lawson Health Research Institute. PERIOP 2, a safety and effectiveness study of LMWH bridging therapy versus placebo bridging therapy for patients on long term warfarin and require temporary interruption of their warfarin. National Library of Medicine. http://clinicaltrialsgov/ct2/show/NCT00432796? term=NCT00432796&rank=1NLM Identifier:NCT00432796. Accessed January 21, 2010.
52. National Heart, Lung and Blood Institute. Effectiveness of bridging anticoagulation for surgery (The BRIDGE Study). National Library of Medicine. http://clinicaltrialsgov/ct2/show/NCT00786474?term=NCT00786474&rank=1NLM Identifier: NCT00786474. Accessed January 20, 2010.
53. Samama MM, Gerotziafas GT. Newer anticoagulants in 2009. J Thromb Thrombolysis. 2010;29(1):92-104.
54. Stangier J, Rathgen K, Stahle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet. 2010;49(4):259-268.
55. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-1151.
56. Golembiewski J, Chernin E, Chopra T. Prevention and treatment of postoperative nausea and vomiting. Am J Health Syst Pharm. 2005;62(12):1247- 1260; quiz 1261-1262.
57. Stangier J, Stahle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet. 2008;47(1):47-59. (Pubitemid 350260888)
58. Eikelboom JE, Weitz JI. Dabigatran etexilate for prevention of venous thromboembolism. Thromb Haemost. 2009;101(1):2-4.
59. Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939, an oral, direct Factor Xa inhibitor, after multiple dosing in healthy male subjects. Eur J Clin Pharmacol. 2005;61(12):873-880. (Pubitemid 41803696)
60. Raghavan N, Frost CE, Yu Z, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos. 2009;37(1):74-81.
61. Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogne JM. Impact of dabigatran on a large panel of routine or specific coagulation assays: laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost. 2012;107(5):985-997.
62. Lindahl TL, Baghaei F, Blixter IF, et al. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost. 2011;105(2):371-378.
63. Samama MM, Martinoli JL, LeFlem L, et al. Assessment of laboratory assays to measure rivaroxaban: an oral, direct factor Xa inhibitor. Thromb Haemost. 2010;103(4):815-825.
64. Castellone DD, Van Cott EM. Laboratory monitoring of new anticoagulants. Am J Hematol. 2010;85(3):185-187.
65. Spyropoulos AC, Turpie AGG, Dunn AS, et al. Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry. J Thromb Haemost. 2006;4(6):1246-1252.